NNVC is the one that really galls me. Here they have been in business much longer than CTIX/IPIX, yet continually change their claim as to what virus they're going to formulate their drug against, and have not managed to initiate a single Phase 1 clinical trial. Yet they continue to extract money from investors and have built a state-of-the-art lab and manufacturing facility, which, when they go into bankruptcy, might fall into the hands of the management or some other creditor.

And is Mako (or some other shortseller) attacking that company? nope.

This is more evidence for the theory that Mako attacks companies whose intellectual property is coveted by some Big Pharma. Why attack NNVC when their intellectual property seems to be worthless -- because why else would they continually kick the can down the road, constantly changing the direction of the company, if they thought that the stuff really worked?

So instead they attack OCAT, with its stem cell technology that worked well (but they had to sell out the company because of the Mako attacks which led them to take toxic financing, which killed them) and IPIX, with its strong pipeline and thankfully its smart management that REFUSES to take toxic financing.

Mako has attacked two companies that had the goods in terms of intellectual property, and didn't attack the one (NNVC) that can't even get a Phase 1 clinical trial going. If someone has another explanation, please tell me.

(And don't say "But NNVC's stock price is so low." There have been a number of times when their price was high enough to warrant a shortseller attack.)